+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 80Years
All Genders
ID07687186

Study of Qishen Yiqi Dripping Pills Compared to Placebo for Treating Chronic Heart Failure With Reduced Ejection Fraction Caused by Coronary Heart Disease

Led by Tasly Pharmaceutical Group Co., Ltd · Updated on 2026-10-23

636

Participants Needed

60

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy and safety of Qishen Yiqi Dripping Pills in treating Chronic Heart Failure with reduced ejection fraction caused by Coronary Heart Disease, specifically in patients with Syndrome of Qi Deficiency with Blood Stasis. This phase 3 randomized controlled trial aims to provide evidence on this traditional Chinese medicine treatment for heart failure. Participants will be randomly assigned to receive either Qishen Yiqi Dripping Pills or a placebo. The treatment involves taking 2 bags of the pills orally, three times a day, half an hour after meals, over a 12-week period. The study uses a quadruple masking design to compare the effects of the active treatment with placebo. During the 12 weeks of treatment, participants will undergo various assessments including the 6-minute walk test, quality of life questionnaires, symptom tracking, echocardiographic measurements, and blood tests for heart function biomarkers at baseline and at weeks 4, 8, and 12. Researchers will monitor exercise capacity, heart failure symptoms, cardiac function, and safety throughout the study to understand the treatments impact and tolerability.

CONDITIONS

Brief Title

Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre

Research Team

R

Rui Liu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here